Research Institute
At Prism Eye Institute, research is integrated into our daily patient care. Through clinical trials, peer-reviewed publications, and academic collaboration, we continuously work to improve outcomes across retina, glaucoma, cataract, cornea, and neuro-ophthalmology.
Improving standard of care thru research
– Access to emerging therapies
– High clinical volume enabling meaningful data
– Collaboration between surgeons and referring optometrists
– Academic & industry partnerships
– Commitment to evidence-based medicine
Meet Our Research Team
Prism Research Institute
Dr. Ike Ahmed
Chief Innovation Officer
Dr. Walid Abdelghaffar
Sub Investigator
Dr. Irfan Kherani
Sub Investigator
Dr. Joshua Teichman
Sub Investigator
Dr. Matt Schlenker
Sub Investigator
Suneet Khurana
Research Manager
David Chen MD
Research Fellow
Maria Orejarena MD
Research Associate
Edward Tran MD
Research Associate
Gabriel Ayub MD
Research Associate
Fareesa Begum
Research Associate
Active Studies
Icare Xen; Watering Drinking Test
Primary Objective
· To detect peak intraocular pressure (IOP) using Water Drinking Test (WDT) and iCare home tonometry, before and after IMS or Xen implantation, to assess efficacy of these procedures.
YESBIO Biocon
Primary Objective
· To describe the patient journey leading to the first intravitreal injection of biosimilar aflibercept (YESAFILI™) in Canadian patients with DME, nAMD, or RVO, including:
o Physician decision-making
o Patient characteristics
o Prior treatment history
o Rationale for selecting a biosimilar over the reference biologic
MF IOLX Puresee study
Primary Objective
· To evaluate patient-reported satisfaction and quality of vision following exchange of a non-tolerated multifocal intraocular lens (MFIOL) to a purely refractive extended depth of focus (EDOF) IOL (TECNIS PureSee™ or PureSee™ Toric), including resolution of dysphotopsias and other visual complaints.
Corvis Study
Primary Objective
· To assess whether baseline corneal biomechanical measurements; corneal hysteresis (CH) and stiffness parameter at first applanation (SP-A1)—predict complete and qualified surgical success up to 1 year following bleb-forming glaucoma surgery
AURN001-NA-LTS study
Primary Objective
· To evaluate the long-term safety of AURN001 and its drug substance constituents (neltependocel and/or Y-27632) in participants with corneal edema secondary to corneal endothelial dysfunction who were previously treated in an AURN001 study.
MIST Study
Primary Objective
· To evaluate the safety, feasibility, and intraocular pressure (IOP)–lowering effect of the MIST device performed ab externo at the slit lamp in patients with primary open-angle glaucoma (POAG).
XEN Multicenter study
Primary Objective
· To compare efficacy and safety outcomes between a surgeon’s first 10 XEN implant cases and subsequent cases (≥11) in order to characterize the learning curve for the ab-interno gelatin stent with Mitomycin C (MMC).
CTA: Do I qualify?
XEN ECC – Endothelial cell density
Primary Objective
· To determine the impact of Xen-45 gelatin stent implantation with mitomycin C (MMC) on post-operative corneal endothelial cell density (ECD) compared with trabeculectomy and tube shunt procedures, as standalone or combined with phacoemulsification.
IOL Calcification
Primary Objective
· To evaluate and compare best-corrected distance and near visual acuity (BCVA) before and after surgical exchange of a calcified intraocular lens (IOLo
iTrack Registry
Primary Objective
· To prospectively collect standardized real-world safety and effectiveness data for glaucoma surgeries involving the iTrack™ or iTrack™ Advance devices, including canaloplasty, GATT, combined MIGS procedures, and procedures combined with micro drug-delivery devices
GLK-411-01 Preserflo Microshunt in POAG
Primary Objective
· To evaluate the safety and effectiveness of the PRESERFLO MicroShunt in adults with primary open-angle glaucoma (POAG) who have failed prior medical and surgical therapy
PanOptix Pro study
Primary Objective
· To evaluate binocular best-corrected distance visual acuity (BCDVA) at 3 months following bilateral PanOptix Pro implantation.
Do I qualify?
Fill out the submission form below to check if you could be eligible to participate for a study.
